Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

Université du Québec à Montréal

$25,000.00

Synthesis of carbohydrate lectin inhibitors as anti-inflammatory drug targets

FY 2012-13

Summary
Bacterial drug resistance is a prevalent and central worldwide bottleneck. Infections with resistant organisms lead to adverse clinical outcomes, increased mortality, and are costly to healthcare systems. Several infectious diseases are initiated by the binding of pathogenic lectins to host cells glycocans. The molecular understanding of these adhesion phenomena is crucial and presents promising new alternatives compared to traditional antibiotic therapies. Glycans mimetics could be used to inhibit the initial recognition events leading to adhesion and colonization of host tissues by pathogens. The bladder and urothelial lining are widely covered by cell surface glycoproteins bearing the required carbohydrate ligands responsible for the adhesion phenomena. However, when these interactions are measured on a per saccharide basis, they are generally too weak for the design of beneficial inhibition therapies. Uropathogenic Escherichia coli (UPEC) strains are the major causal agents of urinary tract infections. During infection, UPEC adhere to mannosylated glycoreceptors on the urothelium via the FimH adhesin located at the tip of type 1 pili. Synthetic FimH anti-adhesives such as modified alpha-D-mannopyranosides are therefore ideal ""hit"" candidates for the chemical interception of this important step in pathogenesis. Roy at UQAM, an expert in the field of glycan mimetics, and Vertex Pharmaceuticals will join their efforts to improve the design of potent inhibitors against fimbriated type 1 E. coli. This will constitute the first collaborative initiative between the two parties. Vertex will be responsible for testing the novel glycomimetics, prepared at UQAM, on their own cell and bacterial strains. They will also offer expertise in computer modeling that will complement crystallographic data obtained by the UQAM team. The company's expertise in drug design will permit a faster guiding in drug development together with knowledge in pharmacokinetic and pharmacodynamic properties. The collaboration will greatly accelerate the development of a new drug candidate. The outcome of this project will be the advancement of the science and discovery of potential drugs.
Program
Engage Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
434720-2012
Name nom
Roy, René
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3702
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Carbohydrates
Research subject fr
Glucides
Partie
1
Nb partie
1
Application title
Synthesis of carbohydrate lectin inhibitors as anti-inflammatory drug targets
Keyword
NSERC
Application summary
Bacterial drug resistance is a prevalent and central worldwide bottleneck. Infections with resistant organisms lead to adverse clinical outcomes, increased mortality, and are costly to healthcare systems. Several infectious diseases are initiated by the binding of pathogenic lectins to host cells glycocans. The molecular understanding of these adhesion phenomena is crucial and presents promising new alternatives compared to traditional antibiotic therapies. Glycans mimetics could be used to inhibit the initial recognition events leading to adhesion and colonization of host tissues by pathogens. The bladder and urothelial lining are widely covered by cell surface glycoproteins bearing the required carbohydrate ligands responsible for the adhesion phenomena. However, when these interactions are measured on a per saccharide basis, they are generally too weak for the design of beneficial inhibition therapies. Uropathogenic Escherichia coli (UPEC) strains are the major causal agents of urinary tract infections. During infection, UPEC adhere to mannosylated glycoreceptors on the urothelium via the FimH adhesin located at the tip of type 1 pili. Synthetic FimH anti-adhesives such as modified alpha-D-mannopyranosides are therefore ideal ""hit"" candidates for the chemical interception of this important step in pathogenesis. Roy at UQAM, an expert in the field of glycan mimetics, and Vertex Pharmaceuticals will join their efforts to improve the design of potent inhibitors against fimbriated type 1 E. coli. This will constitute the first collaborative initiative between the two parties. Vertex will be responsible for testing the novel glycomimetics, prepared at UQAM, on their own cell and bacterial strains. They will also offer expertise in computer modeling that will complement crystallographic data obtained by the UQAM team. The company's expertise in drug design will permit a faster guiding in drug development together with knowledge in pharmacokinetic and pharmacodynamic properties. The collaboration will greatly accelerate the development of a new drug candidate. The outcome of this project will be the advancement of the science and discovery of potential drugs.
Université du Québec à Montréal - $25,000 Grant (2012… | Canada Spends